Celgene acquired Juno Therapeutics for $9 billion and is spending up to $7 billion on Impact Biomedicines in an effort to diversify its hematology portfolio with chimeric antigen receptor T-cell therapies and a JAK2 inhibitor before its best seller, lenalidomide, faces competition from generics.

中文翻译：

---

Celgene大量购买针对血液癌

Celgene以90亿美元的价格收购了Juno Therapeutics，并将斥资70亿美元收购Impact Biomedines，以使其血液学产品系列多样化，包括嵌合抗原受体T细胞疗法和JAK2抑制剂，而其最畅销的产品来那度胺则面临来自仿制药的竞争。